GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Alliance Pharma PLC (LSE:APH) » Definitions » Cash Ratio

Alliance Pharma (LSE:APH) Cash Ratio : 0.53 (As of Jun. 2023)


View and export this data going back to 2001. Start your Free Trial

What is Alliance Pharma Cash Ratio?

The Cash Ratio measures a company’s ability to meet its short-term obligations with cash and near-cash resources. It is calculated as a company's Cash, Cash Equivalents, Marketable Securities divides by its Total Current Liabilities. Alliance Pharma's Cash Ratio for the quarter that ended in Jun. 2023 was 0.53.

Alliance Pharma has a Cash Ratio of 0.53. It indicates that there are more current liabilities than Cash, Cash Equivalents, Marketable Securities, and the company does not have sufficient cash on hand to pay off its short-term debt.

The historical rank and industry rank for Alliance Pharma's Cash Ratio or its related term are showing as below:

LSE:APH' s Cash Ratio Range Over the Past 10 Years
Min: 0.03   Med: 0.18   Max: 0.96
Current: 0.53

During the past 13 years, Alliance Pharma's highest Cash Ratio was 0.96. The lowest was 0.03. And the median was 0.18.

LSE:APH's Cash Ratio is ranked worse than
51.65% of 1028 companies
in the Drug Manufacturers industry
Industry Median: 0.575 vs LSE:APH: 0.53

Alliance Pharma Cash Ratio Historical Data

The historical data trend for Alliance Pharma's Cash Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alliance Pharma Cash Ratio Chart

Alliance Pharma Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Cash Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.12 0.74 0.96 0.72 0.67

Alliance Pharma Semi-Annual Data
Dec13 Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23
Cash Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.71 0.72 0.58 0.67 0.53

Competitive Comparison of Alliance Pharma's Cash Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, Alliance Pharma's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Alliance Pharma's Cash Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Alliance Pharma's Cash Ratio distribution charts can be found below:

* The bar in red indicates where Alliance Pharma's Cash Ratio falls into.



Alliance Pharma Cash Ratio Calculation

The Cash Ratio measures a company's ability to meet its short-term obligations with its cash and near-cash resources.

Alliance Pharma's Cash Ratio for the fiscal year that ended in Dec. 2022 is calculated as:

Cash Ratio (A: Dec. 2022 )=Cash, Cash Equivalents, Marketable Securities/Total Current Liabilities
=31.714/47.022
=0.67

Alliance Pharma's Cash Ratio for the quarter that ended in Jun. 2023 is calculated as:

Cash Ratio (Q: Jun. 2023 )=Cash, Cash Equivalents, Marketable Securities/Total Current Liabilities
=26.112/49.03
=0.53

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Alliance Pharma  (LSE:APH) Cash Ratio Explanation

The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.

The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.

In general, the higher the cash ratio, the better the company's liquidity position.


Alliance Pharma Cash Ratio Related Terms

Thank you for viewing the detailed overview of Alliance Pharma's Cash Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Alliance Pharma (LSE:APH) Business Description

Traded in Other Exchanges
Address
Bath Road, Avonbridge House, Chippenham, Wiltshire, GBR, SN15 2BB
Alliance Pharma PLC is a player in the healthcare market. The company's business includes the acquisition, marketing, and distribution of consumer healthcare and pharmaceutical products. The group operates in two segments: Consumer Healthcare brands and Prescription Medicines. It generates the majority of its revenue from the Consumer Healthcare segment. Its products include Aloclair, Biodermatin, Changmin, Decapional, Effadiane, and Fazol. The company generates maximum revenue from the Kelo-cote brand. Geographically, it derives a majority of its revenue from Europe, the Middle East, and Africa (EMEA).

Alliance Pharma (LSE:APH) Headlines

From GuruFocus

Q4 2018 Amphenol Corp Earnings Call Transcript

By GuruFocus Research 01-22-2024

Q3 2023 Amphenol Corp Earnings Call Transcript

By GuruFocus Research 01-22-2024

Q3 2021 Amphenol Corp Earnings Call Transcript

By GuruFocus Research 01-22-2024

Q3 2019 Amphenol Corp Earnings Call Transcript

By GuruFocus Research 01-22-2024

Q2 2023 Amphenol Corp Earnings Call Transcript

By GuruFocus Research 01-22-2024

Q1 2021 Amphenol Corp Earnings Call Transcript

By GuruFocus Research 01-22-2024

Q4 2020 Amphenol Corp Earnings Call Transcript

By GuruFocus Research 01-22-2024

Q2 2021 Amphenol Corp Earnings Call Transcript

By GuruFocus Research 01-22-2024